Egetis Therapeutics AB (publ) (EGTX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.166x

Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has a cash flow conversion efficiency ratio of -0.166x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-59.00 Million ≈ $-6.35 Million USD) by net assets (Skr355.10 Million ≈ $38.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Egetis Therapeutics AB (publ) defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Egetis Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Egetis Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Egetis Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Metall Zug AG SW:METN	-0.001x
NexPoint Strategic Opportunities Fund NYSE:NXDT	0.002x
Yesco Holdings Co. Ltd KO:015360	0.017x
Sociedad Comercial del Plata S.A. BA:COME	0.036x
PetroVietnam General Services Corp VN:PET	-0.330x
Thirumalai Chemicals Limited NSE:TIRUMALCHM	-0.175x
Síminn hf IC:SIMINN	0.082x
Central Omega Resources Tbk PT JK:DKFT	0.283x

Annual Cash Flow Conversion Efficiency for Egetis Therapeutics AB (publ) (2010–2024)

The table below shows the annual cash flow conversion efficiency of Egetis Therapeutics AB (publ) from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Egetis Therapeutics AB (publ).

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr492.90 Million ≈ $53.04 Million	Skr-227.90 Million ≈ $-24.53 Million	-0.462x	+9.39%
2023-12-31	Skr545.60 Million ≈ $58.72 Million	Skr-278.40 Million ≈ $-29.96 Million	-0.510x	-48.87%
2022-12-31	Skr506.20 Million ≈ $54.48 Million	Skr-173.50 Million ≈ $-18.67 Million	-0.343x	-38.84%
2021-12-31	Skr527.04 Million ≈ $56.72 Million	Skr-130.11 Million ≈ $-14.00 Million	-0.247x	-15.45%
2020-12-31	Skr629.63 Million ≈ $67.76 Million	Skr-134.64 Million ≈ $-14.49 Million	-0.214x	+16.41%
2019-12-31	Skr244.88 Million ≈ $26.35 Million	Skr-62.64 Million ≈ $-6.74 Million	-0.256x	+30.13%
2018-12-31	Skr219.36 Million ≈ $23.61 Million	Skr-80.31 Million ≈ $-8.64 Million	-0.366x	-28.47%
2017-12-31	Skr303.71 Million ≈ $32.68 Million	Skr-86.55 Million ≈ $-9.31 Million	-0.285x	-207.40%
2016-12-31	Skr389.56 Million ≈ $41.92 Million	Skr-36.12 Million ≈ $-3.89 Million	-0.093x	+91.29%
2015-12-31	Skr48.03 Million ≈ $5.17 Million	Skr-51.15 Million ≈ $-5.50 Million	-1.065x	-133.30%
2014-12-31	Skr90.66 Million ≈ $9.76 Million	Skr-41.38 Million ≈ $-4.45 Million	-0.456x	+23.63%
2013-12-31	Skr46.95 Million ≈ $5.05 Million	Skr-28.07 Million ≈ $-3.02 Million	-0.598x	-0.89%
2012-12-31	Skr53.94 Million ≈ $5.80 Million	Skr-31.96 Million ≈ $-3.44 Million	-0.592x	-260.23%
2011-12-31	Skr87.53 Million ≈ $9.42 Million	Skr-14.40 Million ≈ $-1.55 Million	-0.164x	+57.69%
2010-12-31	Skr6.99 Million ≈ $752.22K	Skr-2.72 Million ≈ $-292.41K	-0.389x	--

About Egetis Therapeutics AB (publ)

ST:EGTX Sweden Biotechnology

Market Cap

$227.90 Million

Skr2.12 Billion SEK

Market Cap Rank

#16139 Global

#262 in Sweden

Share Price

Skr5.32

Change (1 day)

+1.33%

52-Week Range

Skr3.97 - Skr6.77

All Time High

Skr57.90